Manufacturing Focus
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Generics CEOs Unplug At AAM Conference
The AAM’s annual Access! 2024 conference brought its much-enjoyed CEOs Unplugged panel to Tampa again for another engaging discussion on critical issues, challenges and opportunities for generics and biosimilars in the US.
COVID To GLP-1: Catalent Plants Ride With Novo To Next Public Health Crisis
A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.
Why Advanced Manufacturing Technologies Haven’t Prevented Drug Shortages – And How They Could
A decade later, another MIT retreat explores factors behind slow adoption of technologies touted in the first – and how the barriers could be overcome to deliver higher-quality, more shortage-proof generic drugs.
Why Did The European Commission Decide All Antimicrobials Should Be Rx-Only?
The European Commission responds to questions regarding its decision to include OTC antivirals and antifungals, including commonly used products like thrush and cold sore creams, in the expanded prescription-only requirements for antimicrobials, as part of proposed measures to combat antimicrobial resistance.
Rentschler’s New CEO On 2024 Expectations For CDMOs
In Vivo caught up with Benedikt von Braunmühl at the recent BIO-Europe conference in Munich, Germany, to discuss his first six weeks as CEO at Rentschler Biopharma and the biggest trends impacting contract development and manufacturing organizations (CDMO).
The Long Learning Curve For Artificially Intelligent Drug Manufacturing Begins Now
Drugmakers quickly adopt low-impact AI/ML models in quest to eventually automate manufacturing processes. Already, they are learning a lot about how these models can support their operations. One finding: innovative change management approaches may be required to unlock their full potential.
Outlook 2024: Shaping A Medtech Environment Where Technology Leads The Way
Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation.
Syngene Eyes Sweet Spot As New Modalities Hog Limelight
Syngene’s CEO discusses its work in ADC development and trends in the CRDMO space as US biotechs navigate a funding squeeze and manufacturing opportunities loom in areas like GLP- 1 receptor agonists.
Manufacturing Devices In The Rollercoaster UK Market
A scale-up strategy is the missing link in the UK devices industry, claims business research organization CPI. Own brand and contract medical manufacturer and packaging company Pennine Healthcare and longstanding medical device CDMO Renfrew Group International give their take on the environment for manufacturers and the opportunities for strengthening the industry base.
CGT Development Is Booming, But Manufacturing Workforce Must Keep Up
Due to the unprecedented growth in the development of cell and gene therapies over the past decade, there is now high demand for certain workforce roles, especially in highly specialized areas and entry-level manufacturing positions.
A Decade At The Top: Lupin MD On Listing Adjacencies, Creating Health Care Continuum
As family-led firms go through a churn in India, Lupin’s MD Nilesh Gupta speaks about adding value via adjacencies to the legacy business, building digital interfaces and a healthcare continuum for patients. In an interview with Scrip, he also emphasized Lupin promoters are neither interested in selling their own stake nor in acquiring that of Cipla’s promoters.
Explaining The Unexplainable: How To Win US FDA’s Trust In Artificially Intelligent Drug Manufacturing
One issue that has surfaced as the pharmaceutical industry responds to the US FDA’s recent discussion paper on manufacturing with AI machine learning models is the question of how to explain what the models are doing.
Evotec Says Sandoz Deal Is ‘Validation’ Of Biologics Ambitions
In the aftermath of announcing a major collaboration with Sandoz on biosimilars, Evotec’s chief business officer Matthias Evers speaks about how the deal provides “validation” of Just-Evotec’s technology platform, while also outlining the firm’s wider ambitions to enable more efficient development of and broader access to biologics.
The E in ESG: Activity-Based Strategies Can Address Climate Impact Of Clinical Research
A partnership approach is required to reduce greenhouse gas emissions generated by pharma clinical studies. That is the advice in this guest contribution by the Sustainable Healthcare Coalition and Johnson & Johnson’s Janssen company to In Vivo’s rolling series on issues in sustainability for healthcare product manufacturers and providers.
‘Context Is All’ – The User’s Role In Healthcare Innovation
Healthcare product innovation and design evolves continually, and COVID-19 times were no exception. But patient-centred design has always been the platform on which medtech businesses build success, says Mike Phillips of outsourcing industrial design company Renfrew Group International.
Mpox And Newfound ‘Punching Power’ Are Bringing Bavarian Nordic Closer To $1bn Target
Bavarian Nordic managed to change its financial story in 2022 when its smallpox vaccine, Jynneos, became a critical tool in the global response to the mpox pandemic. CEO Paul Chaplin speaks to In Vivo about what this year holds in store.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.